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Abstract. Cholangiocarcinoma (CCA) occurs frequently 
in primary sclerosing cholangitis (PSC). Cyclooxygenase-2 
(COX-2) and microsomal prostaglandin E synthase-1 
(mPGES-1) induced by inflammation are believed to mediate 
prostaglandin E2 (PGE2) production thereby promoting 
carcinogenesis. Their expression in PSC-associated CCA 
tissues and non-neoplastic bile duct epithelial cells (BDECs) 
in PSC was investigated. COX-2 and mPGES-1 levels in 
15 PSC patients (7 with CCA) were scored using immu-
nohistochemical staining. The results were compared with 
those obtained in CCA tissues and non-neoplastic BDECs 
(controls) of 15 sporadic CCA patients. Non-neoplastic 
BDECs from large and small bile ducts were investigated 
separately. The mRNA expression levels of COX-2 and 
mPGES-1 in CCA tissues were analyzed by quantita-
tive polymerase chain reaction. Ki-67 immunostaining 
was performed to evaluate cell proliferation. COX-2 was 
strongly expressed in PSC-associated CCA tissues and non-
neoplastic BDECs in PSC. This expression was significantly 
upregulated in both compared with sporadic CCA tissues 
and non-neoplastic BDECs in sporadic CCA (both P<0.01). 
mPGES-1 was expressed at moderate to strong levels in PSC. 
Compared with controls, the expression was significantly 
higher in non-neoplastic small BDECs (P<0.01). COX-2 
mRNA levels were significantly higher in PSC-associated 
tissues than in sporadic CCA tissues (P<0.01). Conversely, 
no differences were observed in mPGES-1 mRNA levels. 
Ki-67 labeling indices were higher in PSC-associated CCA 
tissues and non-neoplastic BDECs in PSC than in controls. 
In conclusion, COX-2 and mPGES-1 were highly expressed 
in PSC-associated CCA tissues and non-neoplastic BDECs in 
PSC, suggesting the involvement of COX-2 and mPGES-1 in 
cholangiocarcinogenesis.
Introduction
Primary sclerosing cholangitis (PSC), a chronic inflamma-
tory disease, is characterized by fibrous thickening of the 
bile duct walls and causes multiple stenoses of the intra- and 
extra-hepatic bile ducts. Cholangiocarcinoma (CCA) occurs 
with high frequency (5-13%) in PSC (1-4). CCA is a prog-
nostic factor for PSC. However, the underlying mechanism of 
carcinogenesis is not well understood.
There are many gastrointestinal cancers that develop 
because of underlying chronic inflammation such as that 
found in PSC. These include gastric cancers caused by 
chronic gastritis due to Helicobacter pylori infection, 
hepatocellular carcinoma caused by chronic hepatitis due 
to hepatitis B virus or hepatitis C virus infection, colorectal 
cancer due to inflammatory bowel disease, and esophageal 
adenocarcinoma due to Barrett's esophagus. The expression of 
cyclooxygenase-2 (COX-2) and microsomal prostaglandin E 
synthase-1 (mPGES-1) is induced by inflammation, and 
studies suggest that these enzymes are involved in the devel-
opment of these carcinomas (5-11). COX-2 and mPGES-1 are 
both involved in the arachidonate cascade: COX-2 converts 
arachidonic acid to prostaglandin H2 (PGH2) and mPGES-1 
converts PGH2 to PGE2. Thus, PGE2 is elevated because of 
increased COX-2 and mPGES-1 expression, and it plays an 
important role in carcinogenesis by promoting cell prolifera-
tion, angiogenesis, cell infiltration and inhibiting apoptosis 
(12). CCA arising in association with PSC (PSC-associated 
CCA) also develops because of underlying chronic inflamma-
tion, which implies the involvement of COX-2 and mPGES-1 
in cholangiocarcinogenesis. However, the mechanism has not 
yet been investigated.
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To elucidate the carcinogenic mechanisms associated with 
PSC, this study investigated COX-2 and mPGES-1 expres-
sion in PSC-associated CCA tissues, CCA unrelated to PSC 
(sporadic CCA) tissues, non-neoplastic bile duct epithelial cells 
(BDECs) in PSC, and non-neoplastic BDECs in sporadic CCA.
Materials and methods
Tissue samples. All tissue samples in this study were obtained 
from Hiroshima University Hospital patients by surgical 
resection or biopsy. PSC tissue samples were obtained from 
15 patients. Seven of these patients had PSC-associated CCA, 
of whom 2 had intrahepatic CCA and 5 had extrahepatic CCA. 
The histological type was well-differentiated tubular adeno-
carcinoma for all patients. The control group was comprised 
of 15 sporadic CCA patients, of whom 7 had intrahepatic CCA 
and 8 had extrahepatic CCA (6 had perihilar extrahepatic bile 
duct tumors and two had distal extrahepatic bile duct tumors). 
Histologically, they were well-differentiated tubular adeno-
carcinomas (6 patients), moderately differentiated tubular 
adenocarcinomas (6 patients), and poorly differentiated tubular 
adenocarcinoma (3 patients).
Sections fixed in 10% buffered formalin for 24 h were used 
for immunohistochemical staining. CCA tissues were frozen 
rapidly in liquid nitrogen and stored at -80˚C before being used 
for reverse transcription-polymerase chain reaction (RT-PCR). 
This study was approved by the Hiroshima University Hospital 
ethics committee.
Immunohistochemistry and evaluation. The streptavidin-biotin 
method was used for immunohistochemical staining of COX-2 
and mPGES-1. Four-micron thick paraffin-embedded sections 
were first deparaffinized and soaked for 30 min in 3% hydrogen 
peroxide solution to inhibit endogenous peroxidase activity. 
They were then soaked in Epitope Retrieval Solution, pH 9.0, at 
95˚C in a hot water bath for 40 min (Novocastra Laboratories 
Ltd., Newcastle upon Tyne, UK). After being washed in phos-
phate-buffered saline (PBS) (pH 7.4), the sections were reacted 
in 10% normal goat serum at room temperature for 10 min in 
order to block non-specific antibody responses. The sections 
were then incubated with primary antibodies overnight at 4˚C. 
The primary antibodies were as follows: polyclonal rabbit 
anti-COX-2 antibodies (Immuno-Biological Laboratories Co. 
Ltd, Gunma, Japan) at a dilution of 1:200 and polyclonal rabbit 
anti-mPGES-1 antibodies (Cayman Chemical, Ann Arbor, MI, 
USA) at a dilution of 1:500. For the control, normal rabbit IgG 
(Santa Cruz Biotechnology, Dallas, TΧ, USA) was used instead 
of the primary antibodies. After washing in PBS, the sections 
were incubated with biotin-labeled secondary antibodies at 
room temperature for 30 min. The sections were then washed 
in PBS and incubated with peroxidase-labeled streptavidin at 
room temperature for 30 min. They were visualized using a 3 
3'-diaminobenzidine tetrahydrochloride substrate (Dako Japan, 
Kyoto, Japan) and counterstained using Mayer's hematoxylin.
Ki-67 immunostaining was performed using Ventana 
BenchMark Ultra (Ventana Medical Systems, Tucson, AZ, 
USA) automatic staining device and rabbit anti-Ki-67 anti-
bodies (Ki-67) as the primary antibody.
COX-2 and mPGES-1 expression in CCA tissues and 
non-neoplastic BDECs was evaluated using a method reported 
previously (13). The staining intensity for each section was 
scored 0-3 as follows: 0, negative staining; 1, weakly positive 
staining; 2, moderately positive staining; and 3, strongly positive 
staining. The maximum intensity of staining and the most exten-
sive intensity level of positive cells were evaluated separately. 
The ‘extent of distribution’ of positive cells for each section was 
scored 0-3 as follows: 0, negative; 1, 1-33%; 2, 34-66%; and 
3, 67-100%. The total score of these three parameters was then 
used to evaluate each section. The median score for each histo-
logical category was used to perform a statistical comparison of 
COX-2 and mPGES-1 immunoreactivity.
Ki-67 was used to calculate the proportion of positive cells 
in CCA tissues and non-neoplastic BDECs. In total, 500 cells 
were counted in areas with many positive cells, and the 
percentage of positive cells relative to the total cell count was 
expressed as the Ki-67 labeling index (LI).
For non-neoplastic BDECs, large BDECs, comprising 
those from the extrahepatic bile duct to the second branches of 
the left and right hepatic ducts, and small BDECs, comprising 
those from septal and interlobular bile ducts, were evaluated 
separately. The non-neoplastic BDECs of sporadic CCA 
patients were used as controls for comparison with those from 
PSC patients.
Immunostaining of cancer tissue was possible for all 
patients. Immunostaining of non-neoplastic large BDECs was 
possible for 11 PSC and 14 control patients. Immunostaining 
of non-neoplastic small BDECs was possible for 9 PSC and 
14 control patients.
RT-PCR. Total RNA was extracted and purified from 
frozen tumor sections using the RNeasy mini kit (Qiagen, 
Germantown, MA, USA). RT-PCR was performed in two 
steps. First, total RNA was converted to cDNA using the 
PrimeScript RT-PCR Kit (Takara Bio Inc., Shiga, Japan). 
A 20 µl reaction mixture containing 200 ng total RNA was 
prepared and subjected to reverse transcription at 42˚C for 
30 min. The mixture was then incubated at 95˚C for 5 min to 
deactivate reverse transcriptase and then cooled to 4˚C.
The Applied Biosystems 7900HT Fast Real-time PCR 
System (Applied Biosystems, Foster City, CA, USA) was used 
to perform RT-PCR. Each PCR reaction mixture contained 1 µl 
cDNA template, 10 µl Power SYBR-Green PCR Master mix 
(Applied Biosystems), 8 pmol primer set, and water to make a 
total volume of 20 µl. First denaturation was performed at 95˚C 
for 10 min and then 50-cycle PCR (95˚C for 10 min, 50˚C for 
1 min) was conducted. Primer sequences were as follows: 
COX-2 sense, 5'-TTCAAATGAGATTGTGGAAAATTGCT-3'; 
antisense, 5'-GATCATCTCTGCCTGAGTATCTT-3'; mPGES-1 
sense, 5'-ACCAGACCATGGGCCAAGAG-3'; antisense 5'-GGC 
CCACCACAATCTGGAA-3'. Amplification results were 
analyzed using sequence detection system 2.4.1 software 
(Applied Biosystems). mRNA expression levels were corrected 
using glyceraldehyde 3-phosphate dehydrogenase as a house-
keeping gene and expressed as arbitrary units.
Statistical analysis. Statistical analysis was performed using 
JMP 9.0.0 (SAS, Cary, NC, USA). All results are expressed as 
means ± SEM. Continuous variables between the two groups 
were compared using the Mann-Whitney U test. P<0.05 was 
considered statistically significant.
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Results
Immunohistochemical analysis of COX-2. Examples of COX-2 
staining are shown in Fig. 1. In PSC-associated CCA tissues 
(Fig. 1a), COX-2 expression was strong in all of the patients. 
In the sporadic CCA tissues (Fig. 1b), COX-2 expression was 
observed for 7/15 patients (47%). In the non-neoplastic large 
BDECs, COX-2 expression was strong for all PSC patients 
(Fig. 1c), whereas the expression was observed in 12 of 15 
control patients (80%; Fig. 1d), and immunoreactivity was 
lower than that in the PSC patients. In the non-neoplastic 
small BDECs, COX-2 expression was moderate to strong for 
all PSC patients (Fig. 1e), whereas the expression was negative 
for 12 of 14 control patients (86%; Fig. 1f). COX-2 expres-
sion scores for the CCA tissues and non-neoplastic BDECs 
are shown in Fig. 2. The scores for the PSC-associated CCA 
tissues were significantly higher (P<0.01) than those for the 
sporadic CCA tissues at 7.57±0.61 and 2.40±0.78, respec-
tively. The scores for the non-neoplastic large BDECs in the 
PSC patients were significantly higher (P<0.01) than those in 
the control patients at 8.55±0.22 and 4.13±0.73, respectively. 
The scores for the non-neoplastic small BDECs in the PSC 
patients were significantly higher (P<0.01) than those for the 
control patients at 6.56±0.75 and 0.86±0.66, respectively. No 
Figure 1. Immunohistochemical staining of COX-2 in CCA cells and non-neoplastic bile duct epithelial cells. Results are as follows: (a) strongly positive in 
PSC-associated CCA; (b) weakly positive in sporadic CCA; (c) strongly positive in large bile duct epithelial cells in PSC; (d) weakly positive in large bile duct 
epithelial cells in controls; (e) strongly positive in small bile duct epithelial cells in PSC; (f) negative staining in small bile duct epithelial cells in controls. Original 
magnification, x200.
Figure 2. Scores representing immunoreactivity of COX-2 in CCA tissues and non-neoplastic bile duct epithelial cells. Data are expressed as means ± SEM.
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significant differences were observed between the scores for 
the non-neoplastic BDECs in the PSC patients with CCA and 
PSC patients without CCA (data not shown).
Immunohistochemical analysis of mPGES-1. Examples of 
mPGES-1 staining are shown in Fig. 3. mPGES-1 expression 
in the PSC-associated CCA tissues (Fig. 3a) was moderate to 
strong for the majority of patients. Expression was observed 
in sporadic CCA tissues (Fig. 3b) in the majority of patients, 
but immunoreactivity in the sporadic CCA tissues was lower 
than that in the PSC-associated CCA tissues. mPGES-1 
expression was moderate to strong in the non-neoplastic 
large BDECs of the majority of PSC tissues (Fig. 3c) and 
control (Fig. 3d) patients. Moderate or higher expression was 
observed in the non-neoplastic small BDECs of 8 of 9 PSC 
patients (89%; Fig. 3e), whereas the expression was nega-
tive in the non-neoplastic small BDECs of 6 of 13 control 
patients (43%; Fig. 3f). The scores for mPGES-1 expression 
are shown in Fig. 4. No significant differences were observed 
between the scores for the PSC-associated and sporadic CCA 
tissues at 6.43±0.40 and 4.67±0.72, respectively. No signifi-
cant differences were observed between the scores for the 
Figure 3. Immunohistochemical staining of mPGES-1 in CCA tissues and non-neoplastic bile duct epithelial cells. Results are as follows: (a) moderately positive 
in PSC-associated CCA tissues; (b) moderately positive in sporadic CCA tissues; (c) strongly positive in large bile duct epithelial cells of PSC; (d) moderately 
positive in large bile duct epithelial cells of controls; (e) strongly positive in small bile duct epithelial cells of PSC; (f) negative staining in small bile duct epithelial 
cells of controls. Original magnification, x200.
Figure 4. Scores representing immunoreactivity of mPGES-1 in CCA tissues and non-neoplastic bile duct epithelial cells. Data are expressed as means ± SEM. 
NS, not significant.
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non-neoplastic large BDECs in the PSC and control patients 
(7.09±0.39 and 5.21±0.68, respectively). However, a trend of 
stronger expression was observed in the non-neoplastic large 
BDECs of the PSC patients. The scores for the non-neoplastic 
small BDECs in the PSC patients were significantly higher 
(P<0.01) than those in the control patients at 5.63±0.92 and 
2.29±0.58, respectively.
Ki-67 labeling index. Examples of Ki-67 staining are shown 
in Fig. 5. The Ki-67 LI results are shown in Fig. 6. No statisti-
cally significant differences were observed between the Ki-67 
LI for the PSC-associated CCA tissues and the sporadic CCA 
tissues at 45.6±8.4 and 33.1±8.8, respectively, although a trend 
of higher Ki-67 LI was observed for the PSC-associated CCA 
tissues. The Ki-67 LI for the non-neoplastic large BDECs in 
the PSC patients were significantly higher (P<0.01) than those 
in the control patients at 13.0±5.3 and 2.1±1.4, respectively. 
No statistically significant differences were observed between 
Ki-67 LI for the non-neoplastic small BDECs of the PSC and 
control patients (4.9±3.5 and 0.28±0.28, respectively), but a 
trend of higher Ki-67 LI was observed in the non-neoplastic 
small BDECs of the PSC.
RT-PCR. COX-2 and mPGES-1 mRNA levels in the CCA 
tissues were evaluated using quantitative real-time PCR. This 
was performed using the tissues samples of 7 PSC-associated 
CCA patients and 15 sporadic CCA patients. The COX-2 
mRNA levels were significantly higher (P<0.05) in the 
PSC-associated CCA tissues than in the sporadic CCA tissues. 
In contrast, no significant differences in mPGES-1 mRNA 
expression were observed between the two groups (Fig. 7).
Discussion
This study indicated that COX-2 and mPGES-1 expression was 
upregulated in both CCA tissues and non-neoplastic BDECs in 
PSC patients. COX-2 expression is known to be upregulated in 
inflammatory diseases that give rise to cancer (5-11) as well as 
in various carcinomas (14-17) and is believed to be involved in 
carcinogenesis and tumor proliferation. High COX-2 expres-
Figure 5. Immunohistochemical staining of Ki-67 in PSC. Results are as follows: (a) PSC-associated CCA tissues; (b) non-neoplastic large bile duct epithelial cells; 
(c) non-neoplastic small bile duct epithelial cells. Original magnification, x200.
Figure 6. Ki-67 labeling index in CCA tissues and non-neoplastic bile duct epithelial cells. Data are expressed as means ± SEM. NS, not significant.
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sion has been reported in non-neoplastic BDECs in PSC 
(18,19). However, the correlation between COX-2 expression 
and carcinogenesis has not yet been investigated in patients. 
It is known that COX-2 is highly expressed in sporadic CCA 
(20-22), which might suggest its involvement in CCA progres-
sion via PGE2 production (23-25). Tsuneoka et al reported that 
a selective COX-2 inhibitor suppressed CCA development in 
hamsters (26), suggesting that COX-2 might be involved in 
cholangiocarcinogenesis. Our study demonstrated marked 
COX-2 expression in non-neoplastic BDECs and CCA tissues 
in PSC. This finding suggests that local PGE2 production 
might be elevated in both non-neoplastic BDECs and CCA 
tissues in PSC. PGE2 exhibits various effects, including cell 
proliferation, angiogenesis, and inhibition of apoptosis, and it 
plays an important role in cancer development and progression 
(12). Ki-67 immunohistochemical staining was performed to 
evaluate the cell proliferative effect of PGE2. Our findings 
demonstrated that cell proliferation was upregulated not only 
in CCA tissues but also in non-neoplastic BDECs in PSC. We 
suggest that in PSC, chronic inflammation could upregulate 
expression of COX-2 and mPGES-1, resulting in increased 
PGE2 production and promotion of carcinogenesis. Previous 
studies have suggested that nitric oxide-induced oxidative 
damage to DNA (27) and gene mutations due to activated cyti-
dine deaminase (28) lead to PSC carcinogenesis. It is therefore 
believed that PGE2 acts as a promoter when BDECs in PSC 
that have acquired gene mutations form tumors and the cancer 
progresses.
This study investigated mPGES-1 expression in PSC. 
mPGES-1 is one of three types of PGES. Similar to COX-2, 
mPGES-1 is an inducible enzyme and its expression level is 
increased by inflammatory irritation (29). mPGES-1 expres-
sion is known to be elevated in various carcinomas (30-34), and 
mPGES-1 might be involved in the carcinogenesis of gastro-
intestinal cancers that develop because of underlying chronic 
inflammation (6,9,11). Lu et al (35) reported that mPGES-1 
is overexpressed in human CCA tissues and that mPGES-1 
promotes CCA development in SCID mice. Our study demon-
strated for the first time that mPGES-1 is highly expressed not 
only in CCA tissues but also in the non-neoplastic BDECs in 
PSC. Cooperation of COX-2 and mPGES-1 might promote 
local PGE2 production.
Although weaker than in those of the PSC patients, COX-2 
and mPGES-1 expression was observed in the non-neoplastic 
large BDECs of the control patients. This might be explained 
as follows. First, the non-neoplastic large BDECs used as 
controls were obtained from sporadic CCA patients. Many of 
these sporadic CCA patients exhibited cholangitis resulting 
from bile duct occlusion. Furthermore, all patients under-
went cholangiography and treatment for obstructive jaundice 
prior to surgery. The irritation associated with temporary 
bile duct inflammation and preoperative treatment might 
have affected COX-2 and mPGES-1 expression. There were 
differences in the levels of COX-2 and mPGES-1 expression 
in the non-neoplastic BDECs of the control patients. COX-2 
and mPGES-1 expression is induced by inflammatory stimu-
lation, but different transcriptional regulatory mechanisms 
are involved in the expression of each. While NF-κB, CRE, 
E-box, and NF-IL6 are believed to be important in the 
transcriptional regulation of COX-2 (36), Egr-1 plays a vital 
role in the transcriptional regulation of mPGES-1 (37). This 
difference might have had an effect on the transcriptional 
differences observed between the two enzymes.
In conclusion, COX-2 and mPGES-1 were highly expressed 
in PSC-associated CCA tissues and non-neoplastic BDECs in 
PSC and were involved in CCA development. However, the 
sample size of this study was small. It is therefore necessary to 
conduct a study using a larger sample size in order to clarify 
Figure 7. Real-time RT-PCR analysis of COX-2 and mPGES-1 mRNA expression in PSC-associated and sporadic CCA tissues. mRNA levels were normalized 
to those of glyceraldehyde 3-phosphate dehydrogenase, a housekeeping gene, and presented as arbitrary units. mRNA expression with the highest copy number 
for each gene was set to 1. NS, not significant.
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the correlations between COX-2/mPGES-1 and CCA carcino-
genesis in PSC.
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